The acidoCEST MR images were processed using MatLab® R2012B (Mathworks, Inc., Natick, MA). All six CEST-FISP images were averaged. To improve the signal-to-noise for individual pixels, a pixel averaging technique was employed that binned 3×3 adjacent pixels, which decreased the original spatial resolution. A second pixel averaging technique was used that applied a Gaussian low-pass filter with the size of 7×7 adjacent pixels with a standard deviation of one pixel, which retained the original image spatial resolution. The CEST spectrum from each of the averaged pixels was smoothed with cubic spline smoothing [22 (link)]. Thereafter, the smoothed CEST spectrum was fitted with a sum of three Lorentzian line shapes, to account for the direct saturation of water and to measure the CEST effects at 4.2 and 5.6 ppm [15 (link)]. The pHe of each averaged pixel with two CEST effects greater than 2√2× noise was determined using an empirical calibration based on chemical solutions of iopromide (Fig. 1d ). This empirical calibration can determine pHe between 6.12 and 7.02 units with a precision of 0.07 pH units. The CEST amplitude at 5.6 ppm is too low to measure tumor pHe≫7.0, and the CEST amplitude at 4.2 ppm is too low to measure tumor pHe≪6.2, at the typical contrast-to-noise levels observed in our in vivo studies with pixelwise analysis. Therefore, we have limited our pH calibration range to approximately pH 6.2 to 7.0. These pixels were represented as colored pixels in the pHe map. Pixels with only a single CEST effect at 4.2 ppm greater than 2√2× noise were set to be pH 7.0. These pixels were represented as white pixels in the pHe map. Using a 2√2× noise threshold ensured that the CEST contrast was due to the agent with 95 % probability [23 (link)]. The extent of contrast agent uptake was the summation of colored pixels and white pixels relative to the total number of pixels that represented the tumor. Notably, this procedure used a systematic algorithm that did not require user intervention, so that the procedure was devoid of bias.
>
Chemicals & Drugs
>
Organic Chemical
>
Iopromide
Iopromide
Iopromide is a nonionic, water-soluble, and low-osmolar iodinated contrast agent commonly used in various radiological procedures.
It is derived from triiodinated benzoic acid and has a molecular formula of C18H24I3N3O8.
Iopromide is characterized by its high iodine content, which enhances the visibility of structures during imaging examinations, such as computed tomography (CT) scans, angiography, and intravenous urography.
Its low osmolarity and non-ionic properties contribute to improved tolerability and reduced risk of adverse reactions compared to earlier-generation contrast agents.
Iopromide is widely utilized in diagnostic imaging to enhance the visualization of blood vessels, organs, and other anatomical structures, aiding in the detection and evaluation of pathological conditions.
It is derived from triiodinated benzoic acid and has a molecular formula of C18H24I3N3O8.
Iopromide is characterized by its high iodine content, which enhances the visibility of structures during imaging examinations, such as computed tomography (CT) scans, angiography, and intravenous urography.
Its low osmolarity and non-ionic properties contribute to improved tolerability and reduced risk of adverse reactions compared to earlier-generation contrast agents.
Iopromide is widely utilized in diagnostic imaging to enhance the visualization of blood vessels, organs, and other anatomical structures, aiding in the detection and evaluation of pathological conditions.
Most cited protocols related to «Iopromide»
Contrast Media
Cuboid Bone
interleukin-24
iopromide
Neoplasms
Strains
A-A-1 antibiotic
Calculi
Catheters
CM 2-3
ECHO protocol
Fat-Free Diet
Infusion Pump
iopromide
Isoflurane
Mus
Neoplasms
Neoplasms by Site
Oxygen
Pulses
Radionuclide Imaging
Reading Frames
Respiratory Rate
Tail
Tissues
Veins
Subjects underwent retrospectively ECG-gated spiral MDCT of the aortic valve region (Somatom Definition Flash, Siemens, Forchheim, Germany). The CT protocol was as follows: tube voltage 100 kV, tube current 320 mAs, pitch 0.23, temporal resolution 75 ms, collimation 2 × 2 × 64 × 0.6 mm. The CM injection protocol included 120 ml of CM (Iopromide, Ultravist 300, Bayer, Berlin, Germany): 20 ml of CM and 15 ml of saline were injected as a test bolus, followed by 75 ml pure CM, 50 ml 50 % CM solution and finally a 50-ml saline flush, all injected at a rate of 7.2 ml/s. Images were reconstructed (0.75 mm slice thickness, 0.7 mm increment, B26f kernel) at 11 time points of the R–R interval: at 20 ms after the R wave and at every 10 % of the R–R interval.
CT protocol
Flushing
iopromide
Multidetector Computed Tomography
Saline Solution
Ultravist 300
Valves, Aortic
The pre‐treatment and post‐treatment CT images were retrieved for analysis. Body weight and height were obtained from medical records within 2 weeks of the initial and follow‐up CT scans. In our institution, routine abdominal and pelvic CT images were obtained for women after intravenous administration of iohexol 300 (Omnipaque 300, GE Healthcare) or iopromide 300 (Ultravist 300, Bayer HealthCare) in a single uniphasic bolus dose of 80–100 mL via a power injector at 2 mL/s. The portal‐venous phase was obtained with a fixed delay of 70 s after the administration of the contrast material, and a pitch between 1.0 and 1.5 before the contrast medium was excreted into the bladder. The following CT image parameters included the following information: contrast‐enhanced, 5 mm slice thickness, 120 kVp, and approximately 290 mA.
Two consecutive transverse CT images extending from L3 to the iliac crest were analysed by using the Varian Eclipse software (Varian Medical Systems Inc., Palo Alto, CA, USA).31 , 37 Predetermined Hounsfield unit (HU) thresholds were −29 to +150 HU for skeletal muscle, −50 to −150 HU for visceral adipose tissue, and −30 to −190 HU for subcutaneous and intermuscular adipose tissues.31 , 32 The cross‐sectional areas (cm2) of the skeletal muscle (including the psoas, paraspinal, transversus abdominis, rectus abdominis, and internal and external oblique muscles) and adipose tissues were calculated. The mean radiation attenuation of the entire cross‐sectional area of the skeletal muscle was the SMD. The total adipose tissue (TAT) area was calculated as the sum of the areas of the subcutaneous, intermuscular, and visceral adipose tissues. The mean tissue areas were calculated by using two consecutive images. One researcher, blinded to the patient information, measured the body composition parameters. The intraobserver coefficients of variation were 0.8%, 0.8%, and 1.0% for the skeletal muscle area, SMD, and TAT area, respectively, in a sample of 60 patients randomly selected from this cohort. The cross‐sectional areas of the skeletal muscle and TAT were normalized based on the patients' height to determine the skeletal muscle index (SMI) and total adipose tissue index (TATI; cm2/m2).
As body composition varies greatly between regions, ethnicities, and cancer types,38 , 39 , 40 , 41 we defined our own cut‐off values for defining sarcopenia, myosteatosis, and low TATI on the basis of previous studies with similar population sizes 7 , 8 , 9 , 15 . Cut‐off values were set at the lowest tertile for SMI and SMD and at the highest tertile for TATI. The post‐treatment body composition change was the difference between the pre‐treatment and post‐treatment CT images. In this study, the median duration to complete PDS and adjuvant chemotherapy was 127 days [interquartile range (IQR): 120–140 days]. The median duration between pre‐treatment and post‐treatment CT scans was 182 days (IQR: 161–225 days). To account for variations in the scan interval duration, body composition changes were calculated as the change per 180 days for providing a standardized unit for comparisons between patients. Per the current definition of cachexia,2 patients with a reduction in the weight, SMI, SMD, or TATI of ≥5% were classified as having ‘loss’;6 patients with a reduction in the weight, SMI, SMD, or TATI of <5% or gain in the weight, SMI, SMD, or TATI were classified as having ‘maintained’.
Two consecutive transverse CT images extending from L3 to the iliac crest were analysed by using the Varian Eclipse software (Varian Medical Systems Inc., Palo Alto, CA, USA).
As body composition varies greatly between regions, ethnicities, and cancer types,
Amides
Glycol, Ethylene
iopromide
Methanol
Neoplasm Metastasis
Protons
Pulse Rate
Radionuclide Imaging
Sodium Hydroxide
Vibration
Most recents protocols related to «Iopromide»
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
All chest CTs were performed with 128-row spiral CT scanners (Somatom x.Site or Somatom Force, Siemens Medical Systems, Erlangen, Germany). The scans were acquired in a craniocaudal direction during a single-breath-hold either contrast-enhanced or non-enhanced. If contrast-enhanced CT was performed, a 1.0 mL/kg body weight bolus of iopromide 370 mg/mL (Ultravist, Bayer, Leverkusen, Germany) was injected intravenously by a power injector with an acquisition time of 75 s. Table 1 shows further technical details.
Full text: Click here
All elective patients scheduled for a contrast-enhanced CT, who filled in a questionnaire evaluating patient comfort, between October 27, 2021 and the end of October 2022 at Maastricht University Medical Center+, were eligible for inclusion. Exclusion criteria were hemodynamic instability, pregnancy, renal insufficiency (estimated glomerular filtration rate <30 mL/min per 1.73 m 2 ), prior adverse reactions to iodinated CM, and age younger than 18 years. Scans conducted at the emergency department scanner were excluded, as the scanning experience for these patients may differ from those who receive a CT scan in outpatient clinical setting. Repeated inclusion was allowed because it was not expected to influence outcome. The 1-year period was divided into 4 periods, each period with a duration of approximately 3 months. Group 1 received CM prewarmed to 37°C (99°F) at a concentration of 370 mg I/mL (iopromide, Ultravist 370; Bayer Healthcare, Berlin, Germany). The same concentration was used in group 2, but at room temperature (~21°C [~73.4°F]). In group 3, the concentration was switched to 300 mg I/mL (iopromide, Ultravist 300; Bayer Healthcare, Berlin, Germany) prewarmed at 37°C. Finally, group 4 received CM 300 mg I/mL at room temperature (Fig. 1). All patients were asked to fill in a questionnaire directly after the CT scan was performed.
To provide an overview of the participation rate, PACS workstation (IDS7 version 24.2; Sectra AB, Linköping, Sweden) was used to compute the total number of contrast-enhanced CT scans conducted during the 4 periods.
To provide an overview of the participation rate, PACS workstation (IDS7 version 24.2; Sectra AB, Linköping, Sweden) was used to compute the total number of contrast-enhanced CT scans conducted during the 4 periods.
All patients underwent a standard multi-phase CECT dedicated to pancreas acquisition in non-enhanced (N), arterial phase (AP), pancreatic parenchymal phase (PPP), and PVP. Iopromide (Ultravist 370, Schering, Berlin, Germany) was administered at a rate of 3.5 mL/sec, with a weight-dependent dose of 1.5 mL/kg. After the contrast agent injection, the average delay times of AP, PPP, and PVP were 25–30 s, 40–50 s, and 65–70 s, respectively. Multiple CT scanners were used because of the retrospective design of this study. The detailed CT scan parameters are listed in Table S1 .
Full text: Click here
All CEM scans were performed with a digital mammography unit (Selenia Dimensions, Hologic Inc., Bedford, MA, USA). Iopromide (Ultravist 300, Bayer, Sacramento, CA, USA), at 1.5 mL per kilogram body weight, was injected intravenously using a power injector at a rate of 3 mL/sec. After 2.5 min, the patient was positioned, and all four images (craniocaudal and mediolateral oblique projections of each breast) were acquired within 10 min. For each view, low-energy exposure (28–33 kVp) and high-energy exposure (45–49 kVp) were obtained at the same time in the same compression. For DBT, a conventional X-ray source was used that sweeps along an arc around the breast to acquire multiple two-dimensional digital images.
Full text: Click here
Top products related to «Iopromide»
Sourced in Germany, United States, Italy, United Kingdom, Switzerland
Ultravist 370 is a non-ionic, water-soluble contrast medium used for radiographic examinations. It contains the active ingredient iopromide and has a concentration of 370 mg iodine per milliliter.
Sourced in Germany, China, France, Italy, United States, United Kingdom
Ultravist is a diagnostic imaging agent used in radiology procedures. It is an iodinated contrast medium that enhances the visibility of organs and structures within the body during medical imaging tests such as computed tomography (CT) scans.
Sourced in Germany, United States, China
Ultravist 300 is a nonionic, water-soluble, iodinated contrast medium used for radiographic procedures. It is a sterile, clear, colorless to pale-yellow solution for intravenous administration. The active ingredient is iopromide, which has a molecular weight of 791.12 g/mol and a chemical formula of C18H24I3N3O8.
Sourced in Germany, United States, Japan, Netherlands, United Kingdom
The SOMATOM Definition Flash is a computed tomography (CT) scanner developed by Siemens. It is designed to provide high-quality imaging for a wide range of medical applications. The SOMATOM Definition Flash utilizes advanced technology to capture detailed images of the body, enabling medical professionals to make accurate diagnoses and inform treatment decisions.
Sourced in Germany, China
Iopromide is a water-soluble contrast agent used in diagnostic imaging procedures, such as computed tomography (CT) scans and angiography. Its core function is to enhance the visibility of internal structures and organs during these imaging examinations.
Sourced in United States, Germany, Japan, United Kingdom, Netherlands
The LightSpeed VCT is a computed tomography (CT) imaging system produced by GE Healthcare. It is designed to provide high-quality, high-speed imaging for a variety of medical applications. The LightSpeed VCT features a multi-slice detector array that enables rapid data acquisition and reconstruction, allowing for efficient patient scanning.
Sourced in United States, Germany, Japan, China, United Kingdom
The Discovery CT750 HD is a computed tomography (CT) scanner developed by GE Healthcare. It is designed to provide high-quality medical imaging for a variety of clinical applications. The core function of this product is to generate detailed cross-sectional images of the body using advanced X-ray technology.
Sourced in Germany, United States, Japan, Netherlands
The Somatom Sensation 16 is a 16-slice computed tomography (CT) scanner manufactured by Siemens. It is designed to capture high-quality images of the human body. The Somatom Sensation 16 utilizes advanced technology to provide efficient and reliable imaging solutions for healthcare professionals.
Sourced in United States, Netherlands, Germany, Japan, Israel
The Brilliance iCT is a computed tomography (CT) imaging system developed by Philips. It is designed to capture high-quality, three-dimensional images of the body for medical diagnostic purposes. The Brilliance iCT utilizes advanced imaging technology to provide detailed visualization of anatomical structures, enabling healthcare professionals to make informed decisions about patient care.
Sourced in Germany, United States, Japan, Netherlands
The Somatom Definition is a computed tomography (CT) scanner developed by Siemens. It is a diagnostic imaging device that uses X-rays to create detailed cross-sectional images of the body.
More about "Iopromide"
Iopromide is a nonionic, water-soluble, and low-osmolar iodinated contrast agent commonly used in various radiological procedures.
It is derived from triiodinated benzoic acid and has a molecular formula of C18H24I3N3O8.
Iopromide is characterized by its high iodine content, which enhances the visibility of structures during imaging examinations, such as computed tomography (CT) scans, angiography, and intravenous urography.
Its low osmolarity and non-ionic properties contribute to improved tolerability and reduced risk of adverse reactions compared to earlier-generation contrast agents like Ultravist 370 and Ultravist.
Iopromide is widely utilized in diagnostic imaging to enhance the visualization of blood vessels, organs, and other anatomical structures, aiding in the detection and evaluation of pathological conditions.
It is commonly used with advanced imaging technologies like SOMATOM Definition Flash, LightSpeed VCT, Discovery CT750 HD, Somatom Sensation 16, and Brilliance iCT, which provide high-quality, detailed images for accurate diagnosis and treatment planning.
Researchers can optimize their Iopromide studies with the help of PubCompare.ai, an AI-powered tool that enhances reproducibility and accuracy by easily locating protocols from literature, pre-prints, and patents, and providing intelligent comparisons to identify the best protocols and products.
Whether you're a clinician, researcher, or radiologist, Iopromide and its related technologies can play a crucial role in your medical imaging and diagnostic practices.
It is derived from triiodinated benzoic acid and has a molecular formula of C18H24I3N3O8.
Iopromide is characterized by its high iodine content, which enhances the visibility of structures during imaging examinations, such as computed tomography (CT) scans, angiography, and intravenous urography.
Its low osmolarity and non-ionic properties contribute to improved tolerability and reduced risk of adverse reactions compared to earlier-generation contrast agents like Ultravist 370 and Ultravist.
Iopromide is widely utilized in diagnostic imaging to enhance the visualization of blood vessels, organs, and other anatomical structures, aiding in the detection and evaluation of pathological conditions.
It is commonly used with advanced imaging technologies like SOMATOM Definition Flash, LightSpeed VCT, Discovery CT750 HD, Somatom Sensation 16, and Brilliance iCT, which provide high-quality, detailed images for accurate diagnosis and treatment planning.
Researchers can optimize their Iopromide studies with the help of PubCompare.ai, an AI-powered tool that enhances reproducibility and accuracy by easily locating protocols from literature, pre-prints, and patents, and providing intelligent comparisons to identify the best protocols and products.
Whether you're a clinician, researcher, or radiologist, Iopromide and its related technologies can play a crucial role in your medical imaging and diagnostic practices.